Serum Levels of Fibroblast Growth Factor 19 Correlate with the Severity of Diarrhea and Independently from Intestinal Inflammation in Patients with Inflammatory Bowel Disease or Microscopic Colitis.
Adult
Biomarkers
/ analysis
Case-Control Studies
Chronic Disease
Colitis
Colitis, Microscopic
Cross-Sectional Studies
Diarrhea
/ etiology
Feces
/ chemistry
Female
Fibroblast Growth Factors
/ blood
Humans
Inflammatory Bowel Diseases
/ blood
Irritable Bowel Syndrome
/ complications
Leukocyte L1 Antigen Complex
/ analysis
Male
Middle Aged
Severity of Illness Index
Journal
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
ISSN: 2148-5607
Titre abrégé: Turk J Gastroenterol
Pays: Turkey
ID NLM: 9515841
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
entrez:
7
7
2021
pubmed:
8
7
2021
medline:
27
1
2022
Statut:
ppublish
Résumé
In chronic diarrhea patients, massive over-reporting symptom-based criteria for functional bowel disorders are pitfalls. There is currently no objective biomarker that may provide a correct correlation with the severity of chronic diarrhea. To clarify the role of fibroblast growth factor-19 (FGF-19) as a biomarker of objective measurements of the severity of diarrhea in comparison with a patientreported outcome, based on the Bristol Stool Form (BSF) Scale. Consecutive 100 patients with chronic diarrhea underwent standard investigations with laboratory tests, fecal calprotectin (FC), endoscopy with biopsies, and serum FGF-19. All patients and 14 healthy controls completed a diary recording, BSF, and stool frequency. We found that irritable bowel syndrome with diarrhea (IBS-D) n = 21/23 (91%) reported a high number on BSF ≥6, compared to patients with inflammatory bowel diseases (IBD) 56/77 (72%) with BSF ≥ 6 (P = .011). FGF-19 median serum levels were significantly lower in Microscopic colitis (0.010 pg/mL) and IBD patients (0.009 pg/mL) compare to IBS-D (266.9 pg/mL) and high levels in healthy subjects (463 pg/mL) (P < .001). Strong inverse correlation of FGF-19 with the stool frequency/day and stool index was found (r = -0.800, P < .001; r = -0.739, P < .001), independently from disease activity (r = -0.718, P = .001; r = -0.792, P = .001). Serum FGF-19 can become a new biomarker for evaluating the severity of diarrhea with objectively and independently from intestinal inflammation. FC and FGF-19 are predictive biomarkers for the organic cause of diarrhea.
Sections du résumé
BACKGROUND
In chronic diarrhea patients, massive over-reporting symptom-based criteria for functional bowel disorders are pitfalls. There is currently no objective biomarker that may provide a correct correlation with the severity of chronic diarrhea. To clarify the role of fibroblast growth factor-19 (FGF-19) as a biomarker of objective measurements of the severity of diarrhea in comparison with a patientreported outcome, based on the Bristol Stool Form (BSF) Scale.
METHODS
Consecutive 100 patients with chronic diarrhea underwent standard investigations with laboratory tests, fecal calprotectin (FC), endoscopy with biopsies, and serum FGF-19. All patients and 14 healthy controls completed a diary recording, BSF, and stool frequency.
RESULTS
We found that irritable bowel syndrome with diarrhea (IBS-D) n = 21/23 (91%) reported a high number on BSF ≥6, compared to patients with inflammatory bowel diseases (IBD) 56/77 (72%) with BSF ≥ 6 (P = .011). FGF-19 median serum levels were significantly lower in Microscopic colitis (0.010 pg/mL) and IBD patients (0.009 pg/mL) compare to IBS-D (266.9 pg/mL) and high levels in healthy subjects (463 pg/mL) (P < .001). Strong inverse correlation of FGF-19 with the stool frequency/day and stool index was found (r = -0.800, P < .001; r = -0.739, P < .001), independently from disease activity (r = -0.718, P = .001; r = -0.792, P = .001).
CONCLUSION
Serum FGF-19 can become a new biomarker for evaluating the severity of diarrhea with objectively and independently from intestinal inflammation. FC and FGF-19 are predictive biomarkers for the organic cause of diarrhea.
Identifiants
pubmed: 34231484
doi: 10.5152/tjg.2021.20247
pmc: PMC8975464
doi:
Substances chimiques
Biomarkers
0
Leukocyte L1 Antigen Complex
0
Fibroblast Growth Factors
62031-54-3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
374-381Références
Gut. 2018 Aug;67(8):1380-1399
pubmed: 29653941
Expert Rev Gastroenterol Hepatol. 2017 Apr;11(4):303-316
pubmed: 28128666
PLoS One. 2011;6(8):e23745
pubmed: 21887309
J Crohns Colitis. 2017 Jun 1;11(6):649-670
pubmed: 28158501
BMJ. 1990 Feb 17;300(6722):439-40
pubmed: 2107897
Gastroenterology. 2017 Feb;152(3):515-532.e2
pubmed: 27773805
Nat Rev Gastroenterol Hepatol. 2014 Jul;11(7):426-34
pubmed: 24662279
Physiol Rev. 2018 Oct 1;98(4):1983-2023
pubmed: 30067158
J Crohns Colitis. 2015 Feb;9(2):125-31
pubmed: 25518063
Rev Esp Enferm Dig. 2019 Jan;111(1):40-45
pubmed: 30284903
J Physiol. 2014 Jul 15;592(14):2967-80
pubmed: 24665101
Aliment Pharmacol Ther. 2015 Jan;41(1):54-64
pubmed: 25329562
United European Gastroenterol J. 2015 Aug;3(4):381-6
pubmed: 26279847
Am J Gastroenterol. 2010 Apr;105(4):814-20; quiz 813, 821
pubmed: 20179688
Cell Metab. 2005 Oct;2(4):217-25
pubmed: 16213224
Clin Gastroenterol. 1986 Jul;15(3):567-82
pubmed: 3742841
Neurogastroenterol Motil. 2018 Feb;30(2):
pubmed: 28799291
J Crohns Colitis. 2019 Mar 26;13(3):273-284
pubmed: 30137278
J Crohns Colitis. 2014 Sep;8(9):1072-8
pubmed: 24666974
Clin Gastroenterol Hepatol. 2019 Dec;17(13):2722-2730.e4
pubmed: 30448597
Neurogastroenterol Motil. 2006 Dec;18(12):1045-55
pubmed: 17109687
Gastroenterology. 2016 Feb 19;:
pubmed: 27144617
Toxicol Sci. 2012 Apr;126(2):446-56
pubmed: 22268002
Digestion. 2004;69(4):211-8
pubmed: 15205569
Gastroenterology. 2013 Sep;145(3):574-82.e1
pubmed: 23727264
Gastroenterology. 2016 May;150(6):1257-61
pubmed: 27147121
Aliment Pharmacol Ther. 2013 Oct;38(8):967-76
pubmed: 23981126
J Neurogastroenterol Motil. 2017 Jan 30;23(1):20-26
pubmed: 27817184